Quarterly ResultMay 6, 2026, 04:18 PM
ADMA Biologics Q1 Revenue $114.5M; Adj. Net Income +22%; Updates FY26 Outlook
AI Summary
ADMA Biologics reported Q1 2026 financial results, with total revenue of $114.5 million, flat year-over-year. Despite competitive market dynamics, Adjusted Net Income grew 22% to $40.7 million and Adjusted EBITDA increased 24% to $59.7 million. The company updated its FY 2026 outlook, expecting total revenue of $530-$560 million, and withdrew long-term guidance. An internal review by the Audit Committee concluded no improper channel stuffing or undisclosed related party transactions.
Key Highlights
- ADMA Biologics updated FY 2026 total revenue outlook to $530M-$560M and withdrew long-term guidance.
- Q1 2026 Total Revenue was $114.5M, flat year-over-year.
- Q1 2026 Adjusted Net Income grew 22% to $40.7M and Adjusted EBITDA increased 24% to $59.7M.
- ASCENIV revenue rose 28% to $97.5M, while BIVIGAM revenue fell 54% to $15.4M.
- Generated $58M in cash from operations and expanded gross margins to 71%.
- Audit Committee review found no improper channel stuffing or undisclosed related party transactions.